Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

The obviousness rejection as a barrier to biotech patent prosecution

Nature Biotechnology volume 27, pages 1125–1126 (2009)Cite this article

An analysis of US Federal Circuit decisions shows the effects of the Supreme Court's decision in KSR v. Teleflex.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Ruiz v. A.B. Chance Co. 234 F.3d 654 (Fed. Cir. 2000).

  2. In re Dembiczak 175 F3.d 994 (Fed. Cir. 1999).

  3. In re Kotzab 217 F.3d 1365, 1371 (Fed. Cir. 2000).

  4. KSR Int'l Co. v. Teleflex, Inc. 550 US 398 (2007).

  5. Wong, H.K. & Lau, D. Nat. Biotechnol. 27, 446–448 (2009).

    Article  CAS  Google Scholar 

  6. Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd. 492 F.3d 1350 (Fed. Cir. 2007).

  7. Pharmastem Therapeutics, Inc. v. Viacell, Inc., et al. 491 F.3d 1342 (Fed. Cir. 2007).

  8. In re Kubin __ F.3d __, No. 2008-1184 (Fed. Cir. 2009).

  9. Pfizer, Inc. v. Apotex, Inc. 480 F.3d 1348 (Fed. Cir. 2007).

  10. In re Peterson 315 F.3d 1325 (Fed. Cir. 2003).

  11. WMS Gaming, Inc. v. Int'l Game Tech. 184 F.3d 1339 (Fed. Cir. 1999).

Download references

Acknowledgements

This study was supported by the National Science Council, Taiwan, Republic of China (grant no. NSC 96-2414-H-075-001), Taipei Veterans General Hospital project (V98C1-190) and Committee on Chinese Medicine and Pharmacy (CCMP97-RD-117). The author would also like thank I.T. Huang, for summarizing the CAFC ruling and H.C. Lee for the statistical analysis.

Author information

Authors and Affiliations

  1. Shyh-Jen Wang is in the Division of Experimental Surgery, Department of Surgery, Taipei Veterans General Hospital and the Institute of Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan, Republic of China.,

    Shyh-Jen Wang

Authors
  1. Shyh-Jen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shyh-Jen Wang.

Supplementary information

Supplementary Text and Figures

Supplementary Table 1 (PDF 252 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, SJ. The obviousness rejection as a barrier to biotech patent prosecution. Nat Biotechnol 27, 1125–1126 (2009). https://doi.org/10.1038/nbt1209-1125

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1209-1125

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing